A phase I/II study of a recombinant chimeric protein composed of transforming growth factor (TGF)-a and a mutated pseudomonas exotoxin termed PE38 (TP-38) in pediatric patients with recurrent or progressive supratentorial high grade gliomas
Phase of Trial: Phase I/II
Latest Information Update: 27 Oct 2009
At a glance
- Drugs TP 38 (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 27 Oct 2009 Actual patient number (3) added as reported by ClinicalTrials.gov.
- 27 Oct 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.